S Dawood1, X Lei2, R Dent3, S Gupta4, B Sirohi4, J Cortes5, M Cristofanilli6, T Buchholz7, A M Gonzalez-Angulo8. 1. Department of Medical Oncology, Dubai Hospital, Dubai, UAE Shaheenah@post.harvard.edu. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. 3. Department of Medical Oncology, Singapore. 4. Department of Breast Medical Oncology, Tata Memorial Centre, Mumbai, India. 5. Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain. 6. Department of Medical Oncology, Thomas Jefferson University, Philadelphia. 7. Departments of Radiation Oncology. 8. Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Abstract
BACKGROUND: Our group has previously reported that women with inflammatory breast cancer (IBC) continue to have worse outcome compared with those with non-IBC. We undertook this population-based study to see if there have been improvements in survival among women with stage III IBC, over time. PATIENT AND METHODS: We searched the Surveillance, Epidemiology and End Results Registry to identify female patients diagnosed with stage III IBC between 1990 and 2010. Patients were divided into four groups according to year of diagnosis: 1990-1995, 1996-2000, 2001-2005, and 2006-2010. Breast cancer-specific survival (BCSS) was estimated using the Kaplan-Meier method and compared across groups using the log-rank test. Cox models were then fit to determine the association of year of diagnosis and BCSS after adjusting for patient and tumor characteristics. RESULTS: A total of 7679 patients with IBC were identified of whom 1084 patients (14.1%) were diagnosed between 1990 and 1995, 1614 patients (21.0%) between 1996 and 2000, 2683 patients (34.9%) between 2001 and 2005, and 2298 patients (29.9%) between 2006 and 2010. The 2-year BCSS for the whole cohort was 71%. Two-year BCSS were 62%, 67%, 72%, and 76% for patients diagnosed between 1990-1995, 1996-2000, 2001-2005, and 2006-2010, respectively (P < 0.0001). In the multivariable analysis, increasing year of diagnosis (modeled as a continuous variable) was associated with decreasing risks of death from breast cancer (HR = 0.98, 95% confidence interval 0.97-0.99, P < 0.0001). CONCLUSION: There has been a significant improvement in survival of patients diagnosed with IBC over a two-decade time span in this large population-based study. This suggests that therapeutic strategies researched and evolved in the context of non-IBC have also had a positive impact in women with IBC.
BACKGROUND: Our group has previously reported that women with inflammatory breast cancer (IBC) continue to have worse outcome compared with those with non-IBC. We undertook this population-based study to see if there have been improvements in survival among women with stage III IBC, over time. PATIENT AND METHODS: We searched the Surveillance, Epidemiology and End Results Registry to identify female patients diagnosed with stage III IBC between 1990 and 2010. Patients were divided into four groups according to year of diagnosis: 1990-1995, 1996-2000, 2001-2005, and 2006-2010. Breast cancer-specific survival (BCSS) was estimated using the Kaplan-Meier method and compared across groups using the log-rank test. Cox models were then fit to determine the association of year of diagnosis and BCSS after adjusting for patient and tumor characteristics. RESULTS: A total of 7679 patients with IBC were identified of whom 1084 patients (14.1%) were diagnosed between 1990 and 1995, 1614 patients (21.0%) between 1996 and 2000, 2683 patients (34.9%) between 2001 and 2005, and 2298 patients (29.9%) between 2006 and 2010. The 2-year BCSS for the whole cohort was 71%. Two-year BCSS were 62%, 67%, 72%, and 76% for patients diagnosed between 1990-1995, 1996-2000, 2001-2005, and 2006-2010, respectively (P < 0.0001). In the multivariable analysis, increasing year of diagnosis (modeled as a continuous variable) was associated with decreasing risks of death from breast cancer (HR = 0.98, 95% confidence interval 0.97-0.99, P < 0.0001). CONCLUSION: There has been a significant improvement in survival of patients diagnosed with IBC over a two-decade time span in this large population-based study. This suggests that therapeutic strategies researched and evolved in the context of non-IBC have also had a positive impact in women with IBC.
Authors: N T Ueno; A U Buzdar; S E Singletary; F C Ames; M D McNeese; F A Holmes; R L Theriault; E A Strom; B J Wasaff; L Asmar; D Frye; G N Hortobagyi Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Eleftherios P Mamounas; John Bryant; Barry Lembersky; Louis Fehrenbacher; Scot M Sedlacek; Bernard Fisher; D Lawrence Wickerham; Greg Yothers; Atilla Soran; Norman Wolmark Journal: J Clin Oncol Date: 2005-05-16 Impact factor: 44.544
Authors: Ana M Gonzalez-Angulo; Bryan T Hennessy; Kristine Broglio; Funda Meric-Bernstam; Massimo Cristofanilli; Sharon H Giordano; Thomas A Buchholz; Aysegul Sahin; S Eva Singletary; Aman U Buzdar; Gabriel N Hortobágyi Journal: Oncologist Date: 2007-08
Authors: Shaheenah Dawood; Kristine Broglio; Yun Gong; Wei-Tse Yang; Massimo Cristofanilli; Shu-Wan Kau; Funda Meric-Bernstam; Thomas A Buchholz; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Massimo Cristofanilli; Ana Maria Gonzalez-Angulo; Aman U Buzdar; Shu-Wan Kau; Debbie K Frye; Gabriel N Hortobagyi Journal: Clin Breast Cancer Date: 2004-02 Impact factor: 3.225
Authors: H Arias-Pulido; A Cimino-Mathews; N Chaher; C Qualls; N Joste; C Colpaert; J D Marotti; M Foisey; E R Prossnitz; L A Emens; S Fiering Journal: Breast Cancer Res Treat Date: 2018-06-01 Impact factor: 4.872
Authors: Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang Journal: Breast Cancer Res Treat Date: 2015-04-07 Impact factor: 4.872
Authors: Hugo Arias-Pulido; Ashley Marie Cimino-Mathews; Nabila Chaher; Clifford Ray Qualls; Nancy Joste; Cecile Colpaert; Jonathan Douglas Marotti; Mary Dickinson Chamberlin; Maxwell Gabriel Foisey; Eric Robert Prossnitz; Leisha Ann Emens; Steven Fiering Journal: Breast Cancer Res Treat Date: 2021-09-20 Impact factor: 4.872
Authors: Ananya Gopika Nair; Vasily Giannakeas; John L Semple; Steven A Narod; David W Lim Journal: Ann Surg Oncol Date: 2022-09-08 Impact factor: 4.339
Authors: Daniel I Hoffman; Patricia Mae G Santos; Macy Goldbach; Luke J Keele; Neil K Taunk; Hannah S Bogen; Laura Burkbauer; Rachel C Jankowitz; Joshua Fosnot; Liza C Wu; Gary M Freedman; Julia C Tchou Journal: Ann Surg Oncol Date: 2021-07-16 Impact factor: 5.344